CDMO
Redesigning ANDA or Novel Drug Products at All Stages for the U.S. Market
Tedor Pharma Services
PAO-08-23-CL-06Sep 26, 2023
Controlled Substances in Clinical Trials
Controlled Substances in Clinical Trials: Considerations, Challenges, and Growing Demand
Rich Nelson; John Hufnagel; Rachel Castro
PCI Pharma Services
PAO-01-23-CL-03Jan 30, 2023